Eli Lilly halves $2.5 billion German factory investment

Eli Lilly will complete only the "minimum scope" of its $2.5 billion factory in Alzey, Germany, halving the project. The plant's shell is nearly finished and 300 workers are already hired, but the expansion to 1,000 jobs is off the table. Hours later, Boehringer Ingelheim cancelled €900 million in planned German investment for 2027–2030. Both companies pointed to the same cause: Berlin's new health-insurance savings law.

Berlin's fiscal corner

The law — the GKV-Beitragssatzstabilisierungsgesetz, or health insurance contribution stabilisation act — responds to a genuine emergency. Germany's average health insurance contribution hit a record 17.5% of gross wages in 2026. The country's council of economic advisers projects total social contributions could reach 49.7% by 2040 without reform. The law targets €16.3 billion in health-system savings by 2027.

For pharma, the mechanism that matters is a "dynamic manufacturer rebate" — a mandatory discount on drug prices that rises automatically as insurance spending grows. Industry groups disagree wildly on how high it could climb: the vfa, Germany's main pharma lobby, projects roughly 20% of list prices by 2030, while Pharma Deutschland, which represents generic and mid-sized drugmakers, warns the figure could reach 50%. That built-in escalation, more than today's rebate level, is what companies say makes long-term planning impossible. Pharma accounts for about 3.3% of health insurance spending but carries roughly 12% of the planned savings.

Paris has the checkbook ready

Boehringer's pivot to France is not an isolated move. On June 1, the company pledged €500 million across four French production sites at Macron's "Choose France" investment summit. Two days later came the €900 million German cancellation. Total pharma investment announced at Choose France: €600 million, triple the previous year.

According to the EY attractiveness barometer, foreign investment projects in Germany have fallen 44% since 2019, while France's decline was 28%. Boehringer's Germany chief put it directly: "The next innovation will, as things stand, not go to Germany".

84% Margins vs. Mandatory Rebates

Eli Lilly posted revenue of $65.2 billion in 2025, up 45% in a single year, with gross margins of 84.3% — meaning 84 cents of every dollar in revenue survived production costs. Boehringer reported €27.8 billion in revenue, up 7.3%. German prices for patented drugs already sit at 114% of the European average. At these margins and price levels, the argument that higher German rebates are commercially unbearable is hard to square with the financials.

This corporate reshuffling exposes the limits of Brussels' power. The EU reached a provisional deal on its Critical Medicines Act in May 2026, designed to bring pharmaceutical production back to Europe. But health-care pricing is a national competence under EU treaties — each government sets its own drug prices, and Brussels cannot override them. The EU can offer incentives to build factories on European soil. It cannot stop a member state from making the investment case worse.

Europe's share of global API (active pharmaceutical ingredient — the chemical compound that makes a drug work) production has fallen from 63% in 1981 to roughly 6% today. The Critical Medicines Act's proposed €5 billion fund is a line item in a future EU budget, not committed money.

Berlin is trapped. It needs to control health costs that squeeze workers and employers paying record contributions. But if the investment flows to Toulouse and Cork instead of Alzey and Ingelheim, the EU's pharmaceutical sovereignty is being dismantled not from Beijing but from inside — by its own member states' fiscal emergencies.